The effects of homocysteine-lowering vitamin supplementation on migraine disability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN34931928

Enrollment

Registered

2007-12-18

Start date

2006-11-30

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine with aura Nervous System Diseases Migraine with aura

Interventions

Daily B vitamin (B6, B9, B12) therapy vs placebo for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Current diagnosis of regular migraine with aura attacks 2. >18 and <70 years old

Exclusion criteria

Exclusion criteria: 1. Co-morbid vascular or neuropsychiatric disease 2. Pregnant 3. Currently taking B vitamins

Design outcomes

Primary

Measure	Time frame
Migraine disability, as measured using the Migraine Disability Assessment (MIDAS) score at baseline and 6 months.	—

Secondary

Measure	Time frame
1. Migraine frequency. Duration of follow-up: 6 months 2. Migraine pain: MIDAS pain score 1-10 (10 = most severe) at baseline and 6 months	—

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026